Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 9, 2026Journal of Food BiochemistryOpen Access

Astragaloside IV significantly mitigated cardiac injury and reduced oxidative stress by inhibiting NOX4 in models of myocardial ischemia-reperfusion injury.

View Full Paper
Ask AI
Bookmark
Share

Key result

Astragaloside IV significantly mitigated cardiac injury and reduced oxidative stress by inhibiting NOX4 in models of myocardial ischemia-reperfusion injury.

Authors

XLXiao Na LiuZLZongyan LiYLYan Liu

Discussion

Loading...

Member takes

Overview

Investigates how Astragaloside IV reduces myocardial ischemia-reperfusion injury, suggesting it as a potential treatment option.

Key Points

  • The study aims to explore the effects of Astragaloside IV on myocardial ischemia-reperfusion injury and its mechanisms.
  • Established myocardial ischemia-reperfusion injury models in Sprague-Dawley rats.
  • Used oxygen-dependent glycan deprivation/reoxygenation (OGD/R) model with H9C2 cell line.
  • Assessed cardiac functional injury, pathological damage, and infarct area.
  • Measured oxidative stress levels and NOX4 expression.
  • AS-IV treatment significantly improved cardiac function and reduced pathological damage.
  • Lowered the infarct area due to ischemia-reperfusion.
  • Reduced oxidative stress levels in both in vitro and in vivo models.
  • Inhibited NOX4 expression to modulate reactive oxygen species production.

Cite This Study

Liu et al. (2026) studied this question. Astragaloside IV significantly mitigated cardiac injury and reduced oxidative stress by inhibiting NOX4 in models of myocardial ischemia-reperfusion injury.

synapsesocial.com/papers/69612fd930ef6c21f6853d97https://doi.org/10.1155/jfbc/2644220
View Full Paper
Ask AI
Bookmark
Share